<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">FEBS Open Bio</journal-id>
<journal-id journal-id-type="iso-abbrev">FEBS Open Bio</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2211-5463</journal-id>
<journal-id journal-id-type="publisher-id">FEB4</journal-id>
<journal-title-group>
<journal-title>FEBS Open Bio</journal-title>
</journal-title-group>
<issn pub-type="epub">2211-5463</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30761250</article-id>
<article-id pub-id-type="pmc">6356171</article-id>
<article-id pub-id-type="doi">10.1002/2211-5463.12559</article-id>
<article-id pub-id-type="publisher-id">FEB412559</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hypoxia affects Slc7a5 expression through <styled-content style="fixed-case">HIF</styled-content>‐2α in differentiated neuronal cells</article-title>
<alt-title alt-title-type="left-running-head">Y. Onishi <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="feb412559-cr-0001">
<name>
<surname>Onishi</surname>
<given-names>Yuki</given-names>
</name>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="feb412559-cr-0002">
<name>
<surname>Hiraiwa</surname>
<given-names>Manami</given-names>
</name>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="feb412559-cr-0003">
<name>
<surname>Kamada</surname>
<given-names>Hikari</given-names>
</name>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="feb412559-cr-0004">
<name>
<surname>Iezaki</surname>
<given-names>Takashi</given-names>
</name>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="feb412559-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="feb412559-cr-0005">
<name>
<surname>Yamada</surname>
<given-names>Takanori</given-names>
</name>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="feb412559-cr-0006">
<name>
<surname>Kaneda</surname>
<given-names>Katsuyuki</given-names>
</name>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="feb412559-cr-0007">
<name>
<surname>Hinoi</surname>
<given-names>Eiichi</given-names>
</name>
<address>
<email>hinoi@p.kanazawa-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="feb412559-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="feb412559-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Laboratory of Molecular Pharmacology</named-content>
<named-content content-type="organisation-division">Division of Pharmaceutical Sciences</named-content>
<institution>Kanazawa University Graduate School</institution>
<country country="JP">Japan</country>
</aff>
<aff id="feb412559-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Venture Business Laboratory</named-content>
<named-content content-type="organisation-division">Organization of Frontier Science and Innovation</named-content>
<institution>Kanazawa University</institution>
<country country="JP">Japan</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
E. Hinoi, Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kanazawa, Ishikawa 920‐1192, Japan<break></break>
Tel/Fax: +81 76 234 4472<break></break>
E‐mail: <email>hinoi@p.kanazawa-u.ac.jp</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2019</year>
</pub-date>
<volume>9</volume>
<issue>2</issue>
<issue-id pub-id-type="doi">10.1002/feb4.2019.9.issue-2</issue-id>
<fpage>241</fpage>
<lpage>247</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Federation of European Biochemical Societies <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:FEB4-9-241.pdf" xlink:type="simple"></self-uri>
<abstract id="feb412559-abs-0001">
<p>An imbalance of branched‐chain amino acids (<styled-content style="fixed-case">BCAA</styled-content>s) in the brain may result in neuropathological conditions, such as autism spectrum disorders. The L‐type amino acid transporter 1 (<styled-content style="fixed-case">LAT</styled-content>1), encoded by the solute carrier transporter 7a5 (<italic>Slc7a5</italic>) gene, is critical for maintaining normal levels of <styled-content style="fixed-case">BCAA</styled-content>s in the brain. However, our understanding of the mechanisms that regulate the expression of <styled-content style="fixed-case">LAT</styled-content>1/<italic>Slc7a5</italic> in neurons is currently limited. Here, we demonstrate that hypoxic conditions result in upregulated expression of <italic>Slc7a5</italic> in differentiated neuronal cells (Neuro2A cells induced to differentiate using all‐<italic>trans</italic> retinoic acid). Mechanistically, hypoxia‐induced expression of <italic>Slc7a5</italic> is markedly reduced by short hairpin <styled-content style="fixed-case">RNA</styled-content> (sh<styled-content style="fixed-case">RNA</styled-content>)‐mediated knockdown of hypoxia‐inducible factor 2α (<styled-content style="fixed-case">HIF</styled-content>‐2α), but not by sh<styled-content style="fixed-case">RNA</styled-content> targeting <styled-content style="fixed-case">HIF</styled-content>‐1α, in differentiated neuronal cells. Moreover, hypoxia increased the binding of <styled-content style="fixed-case">HIF</styled-content>‐2α to the proximal promoter of <italic>Slc7a5</italic> in differentiated neuronal cells. These results indicate that hypoxia directly enhances the recruitment of <styled-content style="fixed-case">HIF</styled-content>‐2α to the proximal promoter of <italic>Slc7a5</italic>, resulting in its upregulated expression in differentiated neuronal cells. These findings indicate that <italic>Slc7a5</italic> may be a novel gene responsive to hypoxia in a <styled-content style="fixed-case">HIF</styled-content>‐2α‐dependent manner in differentiated neuronal cells.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="feb412559-kwd-0001">amino acid transporter</kwd>
<kwd id="feb412559-kwd-0002">branched‐chain amino acid</kwd>
<kwd id="feb412559-kwd-0003">Hif‐2α</kwd>
<kwd id="feb412559-kwd-0004">hypoxia</kwd>
<kwd id="feb412559-kwd-0005">neuron</kwd>
<kwd id="feb412559-kwd-0006">Slc7a5</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Japan Society for the Promotion of Science</funding-source>
<award-id>17KT0051</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="1"></table-count>
<page-count count="7"></page-count>
<word-count count="3606"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>feb412559</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>February 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.5.8 mode:remove_FC converted:01.02.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group id="feb412559-ntgp-0001">
<fn fn-type="equal" id="feb412559-note-1001">
<p>Yuki Onishi and Manami Hiraiwa equally contributed to this work.</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<def-list id="feb412559-dl-0001" list-content="abbreviations">
<title>Abbreviations</title>
<def-item>
<term>ASD</term>
<def>
<p>autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>ATRA</term>
<def>
<p>all‐<italic>trans</italic> retinoic acid</p>
</def>
</def-item>
<def-item>
<term>BBB</term>
<def>
<p>blood–brain barrier</p>
</def>
</def-item>
<def-item>
<term>BCAA</term>
<def>
<p>branched‐chain amino acid</p>
</def>
</def-item>
<def-item>
<term>ChIP</term>
<def>
<p>chromatin immunoprecipitation</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p>central nervous system</p>
</def>
</def-item>
<def-item>
<term>Glut1</term>
<def>
<p>glucose transporter‐1</p>
</def>
</def-item>
<def-item>
<term>HIF</term>
<def>
<p>hypoxia‐inducible factor</p>
</def>
</def-item>
<def-item>
<term>Hmox1</term>
<def>
<p>heme oxygenase‐1</p>
</def>
</def-item>
<def-item>
<term>HRE</term>
<def>
<p>HIF‐responsive element</p>
</def>
</def-item>
<def-item>
<term>LAT</term>
<def>
<p>L‐type amino acid transporter</p>
</def>
</def-item>
<def-item>
<term>mTORC1</term>
<def>
<p>mechanistic target of rapamycin complex 1</p>
</def>
</def-item>
<def-item>
<term>qPCR</term>
<def>
<p>quantitative PCR</p>
</def>
</def-item>
<def-item>
<term>shRNA</term>
<def>
<p>short hairpin RNA</p>
</def>
</def-item>
<def-item>
<term>Slc7a5</term>
<def>
<p>solute carrier transporter 7a5</p>
</def>
</def-item>
</def-list>
<p>It is well recognized that amino acids are capable of regulating cellular function through the modulation of signaling pathways (e.g., the mechanistic target of rapamycin complex 1 [mTORC1]) in various cell types, including the main cell types characterizing the central nervous system (CNS), neurons, and glial cells <xref ref-type="ref" rid="feb412559-bib-0001">1</xref>, <xref ref-type="ref" rid="feb412559-bib-0002">2</xref>, <xref ref-type="ref" rid="feb412559-bib-0003">3</xref>. Moreover, branched‐chain amino acids (BCAAs) serve as precursors for the synthesis of neurotransmitter glutamate. Pathologically high levels of BCAAs, as observed in maple syrup urine disease, cause excessive glutamatergic signaling and neurological symptoms, such as cognitive dysfunctions, seizures, and hypotonia <xref ref-type="ref" rid="feb412559-bib-0004">4</xref>, <xref ref-type="ref" rid="feb412559-bib-0005">5</xref>. Moreover, it has been reported that mutations in the gene encoding branched‐chain keto acid dehydrogenase kinase, the rate‐limiting enzyme in the catabolic pathway of BCAAs, result in autism spectrum disorder (ASD) and fine motor coordination problems because of abnormally low levels of BCAAs in the serum and brain <xref ref-type="ref" rid="feb412559-bib-0006">6</xref>.</p>
<p>Because a constant supply of BCAAs from the periphery is essential for the functions of the brain during development and its homeostasis, factors facilitating the uptake of BCAA may be critical for the proper functioning of the CNS. The L‐type amino acid transporter 1 (LAT1), encoded by the solute carrier transporter 7a5 (<italic>Slc7a5</italic>) gene, forms a heterodimer with a type II glycoprotein, the heavy chain of the 4F2 cell‐surface antigen (4F2hc/CD98), via a disulfide bond <xref ref-type="ref" rid="feb412559-bib-0007">7</xref>, <xref ref-type="ref" rid="feb412559-bib-0008">8</xref>. It has been shown that LAT1 is expressed in the blood–brain barrier (BBB) for maintaining normal levels of BCAAs in the brain. Moreover, LAT1 deficiency in cerebral endothelial cells causes neurological and behavioral abnormalities associated with ASD <xref ref-type="ref" rid="feb412559-bib-0009">9</xref>, <xref ref-type="ref" rid="feb412559-bib-0010">10</xref>, <xref ref-type="ref" rid="feb412559-bib-0011">11</xref>. Although the pivotal expression and crucial role of <italic>Slc7a5</italic> in the BBB (particularly in endothelial cells) have been determined, there is limited evidence regarding the potential expression of <italic>Slc7a5</italic> and molecular mechanisms underlying the regulation of its expression in neuronal cells under pathological conditions.</p>
<p>Hypoxia‐inducible factors (HIFs) are transcription factors that transcriptionally regulate a large number of genes involved in angiogenesis, glycogenesis, and cell survival, promoting adaptation to hypoxic/ischemic stress in response to low tissue oxygenation during ischemic stroke <xref ref-type="ref" rid="feb412559-bib-0012">12</xref>, <xref ref-type="ref" rid="feb412559-bib-0013">13</xref>. HIFs are heterodimers, comprising one of the three major oxygen labile HIF‐α subunits (HIF‐1α, HIF‐2α, or HIF‐3α) and a constitutive HIF‐1β subunit. Among these, the HIF‐1α/HIF‐1β and HIF‐2α/HIF‐1β dimers are the primary factors regulating hypoxic transcriptional responses in most mammalian cells <xref ref-type="ref" rid="feb412559-bib-0014">14</xref>.</p>
<p>In this study, we investigated whether <italic>Slc7a5</italic> is regulated by hypoxia to mimic an ischemic stroke environment in neuronal cells, and the molecular mechanisms underlying the regulation of the expression of <italic>Slc7a5</italic>.</p>
<sec id="feb412559-sec-0002">
<title>Materials and methods</title>
<sec id="feb412559-sec-0003">
<title>Culture of Neuro2A cells</title>
<p>Neuronal Neuro2A cells derived from mouse neuroblastoma exhibited properties of neuronal progenitor cells, committing to neuron‐like cells in the presence of all‐<italic>trans</italic> retinoic acid (ATRA). Undifferentiated Neuro2A cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. Neuro2A cells were inoculated in culture wells at a density of 10<sup>4</sup> cells·mL<sup>−1</sup> in DMEM supplemented with 10% FBS for 24 h, followed by medium change to DMEM supplemented with 2% FBS and 20 μ<sc>m</sc> ATRA for differentiation, as previously described <xref ref-type="ref" rid="feb412559-bib-0015">15</xref>.</p>
<p>Cells were cultured in dishes placed in a jar containing an AnaeroPack™‐Anaero Anaerobic Gas Generator (Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C for 12 h, according to the manufacturer's instructions, to stimulate hypoxia. The oxygen concentration reached a level of &lt; 1% within 1 h <xref ref-type="ref" rid="feb412559-bib-0016">16</xref>.</p>
</sec>
<sec id="feb412559-sec-0004">
<title>Real‐time quantitative polymerase chain reaction (qPCR)</title>
<p>Total RNA was extracted from cells, followed by the synthesis of cDNA using reverse transcriptase and oligo‐dT primers. Subsequently, the cDNA samples were used as templates for real‐time PCR analysis, performed on an MX3005P™ instrument (Agilent Technologies, Santa Clara, CA, USA), using specific primers for each gene (Table <xref ref-type="table" rid="feb412559-tbl-0001">1</xref>). The expression levels of the genes examined were normalized using the <italic>Actb</italic> expression levels as an internal control for each sample <xref ref-type="ref" rid="feb412559-bib-0017">17</xref>.</p>
<table-wrap id="feb412559-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>List of primers used for qPCR in this study</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Genes</th>
<th align="left" colspan="1" rowspan="1" valign="top">Upstream (5′‐3′)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Downstream (5′‐3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Glut1</italic>
</td>
<td align="left" colspan="1" rowspan="1">GAGTGCCTGAAACCAGAGG</td>
<td align="left" colspan="1" rowspan="1">CTCACACTTGGGAGTCA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Hif1a</italic>
</td>
<td align="left" colspan="1" rowspan="1">TCAAGTCAGCAACGTGGAAG</td>
<td align="left" colspan="1" rowspan="1">TATCGAGGCTGTGTCGACTG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Hif2a</italic>
</td>
<td align="left" colspan="1" rowspan="1">GAGGAAGGAGAAATCCCGTGA</td>
<td align="left" colspan="1" rowspan="1">TATGTGTCCGAAGGAAGCTGA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Hmox1</italic>
</td>
<td align="left" colspan="1" rowspan="1">CCAGACACCGCTCCTCCAG</td>
<td align="left" colspan="1" rowspan="1">GGATTTGGGGCTGCTGGTTTC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Slc7a5</italic>
</td>
<td align="left" colspan="1" rowspan="1">ATATCACGCTGCTCAACGGTG</td>
<td align="left" colspan="1" rowspan="1">CTCCAGCATGTAGGCGTAGTC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Slc7a8</italic>
</td>
<td align="left" colspan="1" rowspan="1">TGTGACTGAGGAACTTGTGGA</td>
<td align="left" colspan="1" rowspan="1">GTGGACAGGGCAACAGAAATG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Slc43a1</italic>
</td>
<td align="left" colspan="1" rowspan="1">CTTCCGGGCTTCACCTATCTG</td>
<td align="left" colspan="1" rowspan="1">CCCAATTCCAAATCGCATCCAC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Slc43a2</italic>
</td>
<td align="left" colspan="1" rowspan="1">TGCACCGCTGTGTTGGAAA</td>
<td align="left" colspan="1" rowspan="1">CCGTGCTGTTAGTGACATTCTC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Actb</italic>
</td>
<td align="left" colspan="1" rowspan="1">AAACTGGAACGGTGAAGGCGAC</td>
<td align="left" colspan="1" rowspan="1">CAGAAGCAATGCTGTCACCTTCC</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="feb412559-sec-0005">
<title>Retroviral short hairpin RNA (shRNA) vector and infection</title>
<p>The retroviral shRNA vector for HIF‐1α was previously generated <xref ref-type="ref" rid="feb412559-bib-0018">18</xref>, and the shRNA vector for HIF‐2α was obtained from Sigma. Retroviral vectors were transfected into PLAT‐E cells using the calcium carbonate method. Virus supernatants were collected 48 h after transfection, and the cells were subsequently infected with virus supernatants for 24 h in the presence of 4 μg·mL<sup>−1</sup> polybrene <xref ref-type="ref" rid="feb412559-bib-0019">19</xref>.</p>
</sec>
<sec id="feb412559-sec-0006">
<title>Chromatin immunoprecipitation (ChIP) assay</title>
<p>ChIP experiments were performed according to the manufacturer's protocol <xref ref-type="ref" rid="feb412559-bib-0020">20</xref>. Briefly, Neuro2A cells were incubated with 1% formaldehyde at room temperature for 20 min. After centrifugation of the crosslinked samples, the pellet was homogenized and subjected to sonication using lysis buffer. Immunoprecipitation was performed using the anti‐HIF‐1α (#sc‐10790) (Santa Cruz, Dallas, TX, USA) and anti‐HIF‐2α (#ab199) (Abcam, Cambridge, UK) antibodies. DNA was extracted using phenol/chloroform, and PCR was performed using specific primers: (a) 5′‐ACTTGTGAGGAGGTGTGAGTCG‐3′ and (b) 5′‐TGTTGGTTCAGCTCGCAAAGG‐3′.</p>
</sec>
<sec id="feb412559-sec-0007">
<title>Immunoblotting</title>
<p>Cultured cells were solubilized in lysis buffer containing 1% Nonidet P‐40 detergent. Samples were then subjected to SDS/PAGE, followed by transfer to polyvinylidene fluoride membranes and subsequent immunoblotting with anti‐β‐Actin (#sc‐47778) (Santa Cruz), anti‐p‐p70S6K1 (#9234), and anti‐p70S6K1 (#2708) (Cell Signaling Technology, Danvers, MA, USA).</p>
</sec>
<sec id="feb412559-sec-0008">
<title>Data analysis</title>
<p>All results are expressed as the mean ± standard error of the mean, and statistical significance was determined using the two‐tailed, unpaired Student's <italic>t</italic>‐test, or two‐way analysis of variance using the Bonferroni <italic>post hoc</italic> test.</p>
</sec>
</sec>
<sec id="feb412559-sec-0009">
<title>Results and Discussion</title>
<p>We initially determined the expression of <italic>Slc7a5</italic> in response to hypoxia in cultured neuronal cells. Differentiated Neuro2A cells were exposed to hypoxia for 12 h; further, the expression of <italic>Slc7a5</italic> was determined using qPCR. A marked upregulation in the expression of hypoxia‐responsive genes, such as heme oxygenase‐1 (<italic>Hmox1</italic>) and glucose transporter‐1 (<italic>Glut1</italic>) (Fig. <xref ref-type="fig" rid="feb412559-fig-0001">1</xref>A), was detected in these cells cultured under hypoxia for 12 h. Under this experimental condition, the expression of <italic>Slc7a5</italic> was significantly increased by hypoxia in differentiated Neuro2A cells (Fig. <xref ref-type="fig" rid="feb412559-fig-0001">1</xref>B). In addition to LAT1 (<italic>Slc7a5</italic>), three additional LATs have been identified, namely LAT2 (<italic>Slc7a8</italic>), LAT3 (<italic>Slc43a1</italic>), and LAT4 (<italic>Slc43a2</italic>) <xref ref-type="ref" rid="feb412559-bib-0021">21</xref>. No marked upregulation was observed in the expression of <italic>Slc7a8</italic> with hypoxia in differentiated Neuro2A cells, whereas significant decreases were observed in the expression of <italic>Slc43a1</italic> and <italic>Slc43a2</italic> (Fig. <xref ref-type="fig" rid="feb412559-fig-0001">1</xref>C). In contrast, neither endoplasmic reticulum (ER) stressor tunicamycin at 0.1 μg·mL<sup>−1</sup> nor the oxidative stressor hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) at 100 μ<sc>m</sc> significantly affected <italic>Slc7a5</italic> expression in differentiated Neuro2A cells (Fig. <xref ref-type="fig" rid="feb412559-fig-0001">1</xref>D). These results indicate that the expression of <italic>Slc7a5</italic> was selectively upregulated in differentiated Neuro2A cells by hypoxia but not by ER stressor and oxidative stressor.</p>
<fig fig-type="Figure" id="feb412559-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>
<italic>Slc7a5</italic> expression is upregulated by hypoxia in differentiated Neuro2A cells. Neuro2A cells were differentiated by <styled-content style="fixed-case">ATRA</styled-content> and subsequently cultured for 12 h under hypoxia, followed by determination of <styled-content style="fixed-case">mRNA</styled-content> expression of (A) <italic>Hmox1</italic> and <italic>Glut1</italic>, (B) <italic>Slc7a5</italic>, and (C) <italic>Slc7a8</italic>,<italic> Slc43a1</italic>, and <italic>Slc43a2</italic> by <styled-content style="fixed-case">qPCR</styled-content> (<italic>n</italic> = 4). (D) Neuro2A cells were differentiated by <styled-content style="fixed-case">ATRA</styled-content> and subsequently stimulated with tunicamycin or H<sub>2</sub>O<sub>2</sub> for 12 h, followed by determination of <styled-content style="fixed-case">mRNA</styled-content> expression of <italic>Slc7a5</italic> by <styled-content style="fixed-case">qPCR</styled-content> (<italic>n</italic> = 4). *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, significantly different from the value obtained in cells under normoxia. The data are expressed as the mean ± standard error of the mean; statistical significance was determined using the two‐tailed, unpaired Student's <italic>t</italic>‐test.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="FEB4-9-241-g001"></graphic>
</fig>
<p>We subsequently investigated the regulation of hypoxia‐induced <italic>Slc7a5</italic> expression by HIF, a master transcriptional regulator of the adaptive response to hypoxia. Differentiated Neuro2A cells were retrovirally infected using shRNA for HIF‐1α (shHif‐1α) or HIF‐2α (shHif‐2α), followed by culture under hypoxia for 12 h and subsequent determination of the expression of <italic>Slc7a5</italic>. We initially confirmed that the expression of <italic>Hif1a</italic> or <italic>Hif2a</italic> was significantly decreased in differentiated Neuro2A cells through retroviral infection using shHif‐1α or shHif‐2α, respectively, under both normoxia and hypoxia, without alteration of their expression by hypoxia in cells infected with shControl, shHif‐1α, or shHif‐2α (Fig. <xref ref-type="fig" rid="feb412559-fig-0002">2</xref>A,B). Under these experimental conditions, the expression of <italic>Slc7a5</italic> was markedly increased by hypoxia in cells transfected with shControl. Additionally, a significant upregulation of <italic>Slc7a5</italic> expression under hypoxia was observed in cells transfected with shHif‐1α but not with shHif‐2α. Moreover, the hypoxia‐induced upregulation of the expression of <italic>Slc7a5</italic> was completely blocked through infection with shHif‐2α, but not with shHif‐1α (Fig. <xref ref-type="fig" rid="feb412559-fig-0002">2</xref>C,D). Collectively, the hypoxia‐induced expression of <italic>Slc7a5</italic> was regulated by the transcription factor HIF‐2α in differentiated neuronal cells.</p>
<fig fig-type="Figure" id="feb412559-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>
<italic>Slc7a5</italic> expression is upregulated by hypoxia through <styled-content style="fixed-case">HIF</styled-content>‐2α in differentiated Neuro2A cells. Neuro2A cells retrovirally infected with sh<styled-content style="fixed-case">Hif</styled-content>‐1α or sh<styled-content style="fixed-case">Hif</styled-content>‐2α were differentiated by <styled-content style="fixed-case">ATRA</styled-content>, followed by exposure to hypoxia and subsequent determination of (A) <italic>Hif1a</italic>, (B) <italic>Hif2a</italic>, and (C and D) <italic>Slc7a5</italic> expression. **<italic>P</italic> &lt; 0.01, significantly different from the value obtained in cells under normoxia. <sup>#</sup>
<italic>P</italic> &lt; 0.05, <sup>##</sup>
<italic>P</italic> &lt; 0.01, significantly different from the value obtained in cells infected with shControl. The data are expressed as the mean ± standard error of the mean; statistical significance was determined using the two‐way analysis of variance using the Bonferroni <italic>post hoc</italic> test.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="FEB4-9-241-g002"></graphic>
</fig>
<p>Computational analysis of the 5′‐flanking region of the highly conserved mouse and human <italic>Slc7a5</italic> genes identified one putative HIF‐responsive element (HRE) (Fig. <xref ref-type="fig" rid="feb412559-fig-0003">3</xref>A). Subsequently, we investigated the role of HIF recruitment to the promoter region of the <italic>Slc7a5</italic> gene in the upregulation of the expression of <italic>Slc7a5</italic> in differentiated Neuro2A cells under hypoxic conditions. The cells were exposed to hypoxia for 12 h, followed by immunoprecipitation using the anti‐HIF‐1α or anti‐HIF‐2α antibodies and PCR using primers (primers a and b indicated in Fig. <xref ref-type="fig" rid="feb412559-fig-0003">3</xref>A) to amplify a region containing the HRE of the <italic>Slc7a5</italic> promoter. The recruitment of HIF‐1α to the <italic>Slc7a5</italic> promoter region was equally observed in differentiated Neuro2A cells under normoxia and hypoxia (Fig. <xref ref-type="fig" rid="feb412559-fig-0003">3</xref>B,C). Alternatively, the recruitment of HIF‐2α to the <italic>Slc7a5</italic> promoter region was markedly increased through exposure to hypoxia in differentiated Neuro2A cells (Fig. <xref ref-type="fig" rid="feb412559-fig-0003">3</xref>B,C). These results indicate that HIF‐2α binds directly to the putative binding site located at the <italic>Slc7a5</italic> promoter, leading to the upregulation of the expression of <italic>Slc7a5</italic> under hypoxia in differentiated neuronal cells.</p>
<fig fig-type="Figure" id="feb412559-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Hypoxia increases the recruitment of <styled-content style="fixed-case">HIF</styled-content>‐2α on <italic>Slc7a5</italic> proximal promoter in differentiated Neuro2A cells. (A) Schematic representation of the <italic>Slc7a5</italic> promoter region with putative <styled-content style="fixed-case">HIF</styled-content> binding site in addition to primer regions for Ch<styled-content style="fixed-case">IP</styled-content> assay. (B and C) Neuro2A cells were differentiated by <styled-content style="fixed-case">ATRA</styled-content> and subsequently cultured under hypoxia, followed by Ch<styled-content style="fixed-case">IP</styled-content> assays using the anti‐<styled-content style="fixed-case">HIF</styled-content>‐1α or anti‐<styled-content style="fixed-case">HIF</styled-content>‐2α antibody along with specific primers to amplify the <italic>Slc7a5</italic> promoter containing <styled-content style="fixed-case">HRE</styled-content>. (D) Neuro2A cells were differentiated by <styled-content style="fixed-case">ATRA</styled-content> and subsequently cultured under hypoxia for 12 h, followed by immunoblotting (<italic>n</italic> = 3). *<italic>P</italic> &lt; 0.05, significantly different from the value obtained in cells under normoxia. The data are expressed as the mean ± standard error of the mean; statistical significance was determined using the two‐tailed, unpaired Student's <italic>t</italic>‐test.</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="FEB4-9-241-g003"></graphic>
</fig>
<p>It has been previously shown that the activation of the HIF‐2α pathway was reported to increase mTORC1 activity by upregulating expression of <italic>Slc7a5</italic> in tumor cells and in lung tissue <xref ref-type="ref" rid="feb412559-bib-0022">22</xref>. Accordingly, the finding that hypoxia induces <italic>Slc7a5</italic> expression through HIF‐2α in this study led us to examine whether hypoxia can increase mTORC1 activity in differentiated neuronal cells. The phosphorylated form of p70S6K1, a downstream marker of mTORC1, was markedly increased through exposure to hypoxia for 12 h in differentiated Neuro2A cells (Fig. <xref ref-type="fig" rid="feb412559-fig-0003">3</xref>D), indicating that hypoxia induces not only <italic>Slc7a5</italic> expression but also mTORC1 activation in differentiated neuronal cells.</p>
<p>Maintaining normal levels of BCAAs in the brain is critical for brain homeostasis. Abnormal levels of BCAAs lead to pathophysiological implications such as ASD. In addition to the uptake of BCAAs, LAT1 has been implicated in the delivery of pharmaceutical drugs into the brain, including L‐DOPA and gabapentin, and thyroid hormones <xref ref-type="ref" rid="feb412559-bib-0023">23</xref>, <xref ref-type="ref" rid="feb412559-bib-0024">24</xref>, <xref ref-type="ref" rid="feb412559-bib-0025">25</xref>. Therefore, LAT1 (<italic>Slc7a5</italic>), expressed at the surface of neuronal cells, may play a crucial role in drug delivery and hormonal input into the brain, in addition to amino acid sensing.</p>
<p>It should be noted that hypoxia decreased mRNA expression of <italic>Slc43a1</italic> and <italic>Slc43a2</italic>, which do not contain conserved HRE between mouse and human, in differentiated Neuro2A cells. Although the exact mechanism underlying the downregulation of <italic>Slc43a1</italic> and <italic>Slc43a2</italic> should be elucidated, in this study, we focused on the regulatory mechanism by which hypoxia/HIF axis controls the expression of <italic>Slc7a5</italic>.</p>
<p>In this study, we demonstrated that the amino acid transporter gene <italic>Slc7a5</italic> may be a novel gene responsive to hypoxia in a HIF‐2α‐dependent manner in differentiated neuronal cells. <italic>Slc7a5</italic> global knockout in mice is embryonically lethal at E9.5–10.5. Therefore, the <italic>in vivo</italic> vital role of <italic>Slc7a5</italic> expressed by neurons in the development, homeostasis, and pathology of the CNS remains highly unclear <xref ref-type="ref" rid="feb412559-bib-0026">26</xref>. mTORC1 is implicated in neurodegenerative and neuropsychiatric diseases as well as in various physiological brain functions, including learning, memory, and synaptic plasticity <xref ref-type="ref" rid="feb412559-bib-0027">27</xref>. Additional studies are warranted to determine the crucial role of upregulated <italic>Slc7a5</italic> in neuronal functions by hypoxic condition. However, the fact that hypoxia increased both <italic>Slc7a5</italic> expression through HIF‐2α and mTORC1 activity in differentiated neuronal cells suggests one possible but hitherto unidentified speculation that hypoxia/HIF‐2α/LAT1 axis in neurons can be implicated in the modulation of mTORC1‐dependent neuronal function under physiological and pathological conditions. In any case, LAT1 (<italic>Slc7a5</italic>) expressed in neurons may be a target for the discovery and development of novel therapeutic agents against various neurodegenerative and neuropsychiatric diseases.</p>
</sec>
<sec id="feb412559-sec-0011">
<title>Conflict of interest</title>
<p>The authors declare no conflict of interest.</p>
</sec>
<sec id="feb412559-sec-0012">
<title>Author contributions</title>
<p>YO and EH conceived and designed the study. YO, MH, HK, TI, and TY performed experiments. KK and EH discussed the results and provided comments. YO and EH wrote the manuscript.</p>
</sec>
</body>
<back>
<ack id="feb412559-sec-0010">
<title>Acknowledgement</title>
<p>This work was supported in part by the Japan Society for the Promotion of Science (17KT0051 to EH).</p>
</ack>
<ref-list content-type="cited-references" id="feb412559-bibl-0001">
<title>References</title>
<ref id="feb412559-bib-0001">
<label>1</label>
<mixed-citation id="feb412559-cit-0001" publication-type="journal">
<string-name>
<surname>Costa‐Mattioli</surname>
<given-names>M</given-names>
</string-name> and <string-name>
<surname>Monteggia</surname>
<given-names>LM</given-names>
</string-name> (<year>2013</year>) <article-title>mTOR complexes in neurodevelopmental and neuropsychiatric disorders</article-title>. <source xml:lang="en"/>Nat Neurosci
<volume>16</volume>, <fpage>1537</fpage>–<lpage>1543</lpage>.<pub-id pub-id-type="pmid">24165680</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0002">
<label>2</label>
<mixed-citation id="feb412559-cit-0002" publication-type="journal">
<string-name>
<surname>Takei</surname>
<given-names>N</given-names>
</string-name> and <string-name>
<surname>Nawa</surname>
<given-names>H</given-names>
</string-name> (<year>2014</year>) <article-title>mTOR signaling and its roles in normal and abnormal brain development</article-title>. <source xml:lang="en"/>Front Mol Neurosci
<volume>7</volume>, <fpage>28</fpage>.<pub-id pub-id-type="pmid">24795562</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0003">
<label>3</label>
<mixed-citation id="feb412559-cit-0003" publication-type="journal">
<string-name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</string-name> (<year>2017</year>) <article-title>Twenty‐five years of mTOR: Uncovering the link from nutrients to growth</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci U S A
<volume>114</volume>, <fpage>11818</fpage>–<lpage>11825</lpage>.<pub-id pub-id-type="pmid">29078414</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0004">
<label>4</label>
<mixed-citation id="feb412559-cit-0004" publication-type="journal">
<string-name>
<surname>Menkes</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Hurst</surname>
<given-names>PL</given-names>
</string-name> and <string-name>
<surname>Craig</surname>
<given-names>JM</given-names>
</string-name> (<year>1954</year>) <article-title>A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance</article-title>. <source xml:lang="en"/>Pediatrics
<volume>14</volume>, <fpage>462</fpage>–<lpage>467</lpage>.<pub-id pub-id-type="pmid">13214961</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0005">
<label>5</label>
<mixed-citation id="feb412559-cit-0005" publication-type="journal">
<string-name>
<surname>Zinnanti</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Lazovic</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Skvorak</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Homanics</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Bewley</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Lanoue</surname>
<given-names>KF</given-names>
</string-name> and <string-name>
<surname>Flanagan</surname>
<given-names>JM</given-names>
</string-name> (<year>2009</year>) <article-title>Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease</article-title>. <source xml:lang="en"/>Brain
<volume>132</volume>, <fpage>903</fpage>–<lpage>918</lpage>.<pub-id pub-id-type="pmid">19293241</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0006">
<label>6</label>
<mixed-citation id="feb412559-cit-0006" publication-type="journal">
<string-name>
<surname>Novarino</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>El‐Fishawy</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kayserili</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Meguid</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Schroth</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Silhavy</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Kara</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Khalil</surname>
<given-names>RO</given-names>
</string-name>, <string-name>
<surname>Ben‐Omran</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Mutations in BCKD‐kinase lead to a potentially treatable form of autism with epilepsy</article-title>. <source xml:lang="en"/>Science
<volume>338</volume>, <fpage>394</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">22956686</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0007">
<label>7</label>
<mixed-citation id="feb412559-cit-0007" publication-type="journal">
<string-name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Segawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miyamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Uchino</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeda</surname>
<given-names>E</given-names>
</string-name> and <string-name>
<surname>Endou</surname>
<given-names>H</given-names>
</string-name> (<year>1998</year>) <article-title>Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)</article-title>. <source xml:lang="en"/>J Biol Chem
<volume>273</volume>, <fpage>23629</fpage>–<lpage>23632</lpage>.<pub-id pub-id-type="pmid">9726963</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0008">
<label>8</label>
<mixed-citation id="feb412559-cit-0008" publication-type="journal">
<string-name>
<surname>Mastroberardino</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Spindler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Pfeiffer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Skelly</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Loffing</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shoemaker</surname>
<given-names>CB</given-names>
</string-name> and <string-name>
<surname>Verrey</surname>
<given-names>F</given-names>
</string-name> (<year>1998</year>) <article-title>Amino‐acid transport by heterodimers of 4F2hc/CD98 and members of a permease family</article-title>. <source xml:lang="en"/>Nature
<volume>395</volume>, <fpage>288</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">9751058</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0009">
<label>9</label>
<mixed-citation id="feb412559-cit-0009" publication-type="journal">
<string-name>
<surname>Duelli</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Enerson</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Gerhart</surname>
<given-names>DZ</given-names>
</string-name> and <string-name>
<surname>Drewes</surname>
<given-names>LR</given-names>
</string-name> (<year>2000</year>) <article-title>Expression of large amino acid transporter LAT1 in rat brain endothelium</article-title>. <source xml:lang="en"/>J Cereb Blood Flow Metab
<volume>20</volume>, <fpage>1557</fpage>–<lpage>1562</lpage>.<pub-id pub-id-type="pmid">11083230</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0010">
<label>10</label>
<mixed-citation id="feb412559-cit-0010" publication-type="journal">
<string-name>
<surname>Pardridge</surname>
<given-names>WM</given-names>
</string-name> (<year>2015</year>) <article-title>Blood‐brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery</article-title>. <source xml:lang="en"/>Exp Opin Ther Targets
<volume>19</volume>, <fpage>1059</fpage>–<lpage>1072</lpage>.</mixed-citation>
</ref>
<ref id="feb412559-bib-0011">
<label>11</label>
<mixed-citation id="feb412559-cit-0011" publication-type="journal">
<string-name>
<surname>Tarlungeanu</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Deliu</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dotter</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Kara</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Janiesch</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Scalise</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Galluccio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tesulov</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morelli</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sonmez</surname>
<given-names>FM</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder</article-title>. <source xml:lang="en"/>Cell
<volume>167</volume>, <fpage>1481</fpage>–<lpage>1494.e18</lpage>.<pub-id pub-id-type="pmid">27912058</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0012">
<label>12</label>
<mixed-citation id="feb412559-cit-0012" publication-type="journal">
<string-name>
<surname>Simon</surname>
<given-names>MC</given-names>
</string-name> (<year>2016</year>) <article-title>The hypoxia response pathways ‐ hats off!</article-title>. <source xml:lang="en"/>N Engl J Med
<volume>375</volume>, <fpage>1687</fpage>–<lpage>1689</lpage>.<pub-id pub-id-type="pmid">27618882</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0013">
<label>13</label>
<mixed-citation id="feb412559-cit-0013" publication-type="journal">
<string-name>
<surname>Semenza</surname>
<given-names>GL</given-names>
</string-name> (<year>2017</year>) <article-title>Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype</article-title>. <source xml:lang="en"/>EMBO J
<volume>36</volume>, <fpage>252</fpage>–<lpage>259</lpage>.<pub-id pub-id-type="pmid">28007895</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0014">
<label>14</label>
<mixed-citation id="feb412559-cit-0014" publication-type="journal">
<string-name>
<surname>Dengler</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Galbraith</surname>
<given-names>M</given-names>
</string-name> and <string-name>
<surname>Espinosa</surname>
<given-names>JM</given-names>
</string-name> (<year>2014</year>) <article-title>Transcriptional regulation by hypoxia inducible factors</article-title>. <source xml:lang="en"/>Crit Rev Biochem Mol Biol
<volume>49</volume>, <fpage>1</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">24099156</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0015">
<label>15</label>
<mixed-citation id="feb412559-cit-0015" publication-type="journal">
<string-name>
<surname>Takarada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fukumori</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kutsukake</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kuramoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hinoi</surname>
<given-names>E</given-names>
</string-name> and <string-name>
<surname>Yoneda</surname>
<given-names>Y</given-names>
</string-name> (<year>2016</year>) <article-title>Protective upregulation of activating transcription factor‐3 against glutamate neurotoxicity in neuronal cells under ischemia</article-title>. <source xml:lang="en"/>J Neurosci Res
<volume>94</volume>, <fpage>378</fpage>–<lpage>388</lpage>.<pub-id pub-id-type="pmid">26900013</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0016">
<label>16</label>
<mixed-citation id="feb412559-cit-0016" publication-type="journal">
<string-name>
<surname>Hinoi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ochi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takarada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakatani</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Iezaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakajima</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takahata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hidano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia</article-title>. <source xml:lang="en"/>J Bone Min Res
<volume>27</volume>, <fpage>938</fpage>–<lpage>949</lpage>.</mixed-citation>
</ref>
<ref id="feb412559-bib-0017">
<label>17</label>
<mixed-citation id="feb412559-cit-0017" publication-type="journal">
<string-name>
<surname>Fukasawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Iezaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Horie</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kanayama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ozaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takahata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yoneda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takarada</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>ATF3 controls proliferation of osteoclast precursor and bone remodeling</article-title>. <source xml:lang="en"/>Sci Rep
<volume>6</volume>, <fpage>30918</fpage>.<pub-id pub-id-type="pmid">27480204</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0018">
<label>18</label>
<mixed-citation id="feb412559-cit-0018" publication-type="journal">
<string-name>
<surname>Horie</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fukasawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iezaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ozaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kanayama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hiraiwa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitaguchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kaneda</surname>
<given-names>K</given-names>
</string-name>
<italic>et al</italic> (<year>2018</year>) <article-title>Hypoxic stress upregulates the expression of Slc38a1 in Brown adipocytes via hypoxia‐inducible factor‐1alpha</article-title>. <source xml:lang="en"/>Pharmacology
<volume>101</volume>, <fpage>64</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">29065407</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0019">
<label>19</label>
<mixed-citation id="feb412559-cit-0019" publication-type="journal">
<string-name>
<surname>Iezaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Horie</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fukasawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kitabatake</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ozaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kanayama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hiraiwa</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic> (<year>2018</year>) <article-title>Translational control of Sox9 RNA by mTORC1 contributes to skeletogenesis</article-title>. <source xml:lang="en"/>Stem Cell Rep
<volume>11</volume>, <fpage>228</fpage>–<lpage>241</lpage>.</mixed-citation>
</ref>
<ref id="feb412559-bib-0020">
<label>20</label>
<mixed-citation id="feb412559-cit-0020" publication-type="journal">
<string-name>
<surname>Iezaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ozaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fukasawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kitajima</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Muneta</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takeda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Horie</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>ATF3 deficiency in chondrocytes alleviates osteoarthritis development</article-title>. <source xml:lang="en"/>J Pathol
<volume>239</volume>, <fpage>426</fpage>–<lpage>437</lpage>.<pub-id pub-id-type="pmid">27159257</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0021">
<label>21</label>
<mixed-citation id="feb412559-cit-0021" publication-type="journal">
<string-name>
<surname>Verrey</surname>
<given-names>F</given-names>
</string-name> (<year>2003</year>) <article-title>System L: heteromeric exchangers of large, neutral amino acids involved in directional transport</article-title>. <source xml:lang="en"/>Pflugers Arch
<volume>445</volume>, <fpage>529</fpage>–<lpage>533</lpage>.<pub-id pub-id-type="pmid">12634921</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0022">
<label>22</label>
<mixed-citation id="feb412559-cit-0022" publication-type="journal">
<string-name>
<surname>Elorza</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Soro‐Arnaiz</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Melendez‐Rodriguez</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rodriguez‐Vaello</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Marsboom</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>de Carcer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Acosta‐Iborra</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Albacete‐Albacete</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ordonez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Serrano‐Oviedo</surname>
<given-names>L</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>HIF2alpha acts as an mTORC1 activator through the amino acid carrier SLC7A5</article-title>. <source xml:lang="en"/>Mol Cell
<volume>48</volume>, <fpage>681</fpage>–<lpage>691</lpage>.<pub-id pub-id-type="pmid">23103253</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0023">
<label>23</label>
<mixed-citation id="feb412559-cit-0023" publication-type="journal">
<string-name>
<surname>Alexander</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Schwartzman</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Grothusen</surname>
<given-names>JR</given-names>
</string-name> and <string-name>
<surname>Gordon</surname>
<given-names>SW</given-names>
</string-name> (<year>1994</year>) <article-title>Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood‐to‐brain transport of levodopa in naive and MPTP parkinsonian monkeys</article-title>. <source xml:lang="en"/>Neurology
<volume>44</volume>, <fpage>1491</fpage>–<lpage>1499</lpage>.<pub-id pub-id-type="pmid">8058155</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0024">
<label>24</label>
<mixed-citation id="feb412559-cit-0024" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name> and <string-name>
<surname>Welty</surname>
<given-names>DF</given-names>
</string-name> (<year>1996</year>) <article-title>The simultaneous estimation of the influx and efflux blood‐brain barrier permeabilities of gabapentin using a microdialysis‐pharmacokinetic approach</article-title>. <source xml:lang="en"/>Pharm Res
<volume>13</volume>, <fpage>398</fpage>–<lpage>403</lpage>.<pub-id pub-id-type="pmid">8692732</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0025">
<label>25</label>
<mixed-citation id="feb412559-cit-0025" publication-type="journal">
<string-name>
<surname>Friesema</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Docter</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moerings</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Verrey</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Krenning</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Hennemann</surname>
<given-names>G</given-names>
</string-name> and <string-name>
<surname>Visser</surname>
<given-names>TJ</given-names>
</string-name> (<year>2001</year>) <article-title>Thyroid hormone transport by the heterodimeric human system L amino acid transporter</article-title>. <source xml:lang="en"/>Endocrinology
<volume>142</volume>, <fpage>4339</fpage>–<lpage>4348</lpage>.<pub-id pub-id-type="pmid">11564694</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0026">
<label>26</label>
<mixed-citation id="feb412559-cit-0026" publication-type="journal">
<string-name>
<surname>Poncet</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>FE</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>McGuire</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>English</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Arthur</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>YB</given-names>
</string-name> and <string-name>
<surname>Taylor</surname>
<given-names>PM</given-names>
</string-name> (<year>2014</year>) <article-title>The catalytic subunit of the system L1 amino acid transporter (slc7a5) facilitates nutrient signalling in mouse skeletal muscle</article-title>. <source xml:lang="en"/>PLoS One
<volume>9</volume>, <fpage>e89547</fpage>.<pub-id pub-id-type="pmid">24586861</pub-id></mixed-citation>
</ref>
<ref id="feb412559-bib-0027">
<label>27</label>
<mixed-citation id="feb412559-cit-0027" publication-type="journal">
<string-name>
<surname>Lipton</surname>
<given-names>JO</given-names>
</string-name> and <string-name>
<surname>Sahin</surname>
<given-names>M</given-names>
</string-name> (<year>2014</year>) <article-title>The neurology of mTOR</article-title>. <source xml:lang="en"/>Neuron
<volume>84</volume>, <fpage>275</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">25374355</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>